Ertapenem for Foot Infections in Diabetes without Osteomyelitis
The U.S. Food and Drug Administration (FDA) has approved ertapenem (Invanz®, Merck), a once-daily injectable antibiotic, for the treatment of moderate-to-severe complicated foot infections caused by pathogens in diabetic patients without osteomyelitis.
This medication was approved in 2001 for adults with moderate-to-severe infections caused by common gram-positive and gram-negative aerobic and anaerobic bacteria.
buy altace online
Ertapenem is a carbapenem related to the class of antibiotics known as beta-lactams. The adult dose is generally 1 g once daily by intravenous (IV) infusion or intramuscular injection. The cream should be used only to treat or prevent infections that are thought to be caused by susceptible bacteria.
